They proposed a biological scoring system that included EVI-1, PRAME, and ERG and that allowed patient stratification into four significantly different prognostic groups, both in the whole CN-AML population and in those patients with a typical intermediate prognosis (the FLT3-ITD negative/NPM negative and the FLT3-ITD positive/NPM positive) [6]. This evidence concerns the gene FLT3 and acute myeloid leukemia.